Advertisement

Osteoporosis International

, Volume 28, Issue 5, pp 1587–1595 | Cite as

Use of proton pump inhibitors and mortality after hip fracture in a nationwide study

  • W. BrozekEmail author
  • B. Reichardt
  • J. Zwerina
  • H. P. Dimai
  • K. Klaushofer
  • E. Zwettler
Original Article

Abstract

Summary

We analyzed the association of proton pump inhibitors (PPIs) with mortality after osteoporosis-related hip fracture in Austria. PPIs were associated with reduced 90-day mortality but elevated mortality after half a year when initiated pre-fracture. Inpatients and discharged patients on PPIs showed lowered in-hospital and 90-day mortality, respectively.

Introduction

We herein investigated use of proton pump inhibitors (PPIs) and mortality among hip fracture patients in a nationwide study in Austria.

Methods

In this retrospective cohort study, data on use of PPIs were obtained from 31,668 Austrian patients ≥50 years with a hip fracture between July 2008 and December 2010. All-cause mortality in patients without anti-osteoporotic drug treatment who had received their first recorded PPI prescription in the study period either before or after fracture was compared with hip fracture patients on neither PPIs nor anti-osteoporotic medication using logistic and Cox regression analysis.

Results

With PPI use, 90-day mortality was significantly reduced, both at initiation before (OR 0.66; p < 0.0001) and after hip fracture (OR 0.23; p < 0.0001). 90-day mortality was also reduced when PPIs were prescribed not until after discharge from the last recorded hip fracture-related hospital stay (OR 0.49; p < 0.0001) except for patients aged <70 years. In a sub-cohort of patients beginning PPIs during hospital stay, in-hospital mortality (0.2%) was substantially reduced relative to matched control patients (3.5%) (p < 0.0001). Longer-term mortality significantly increased after half a year post-fracture only among those who started PPI prescription before fracture.

Conclusions

PPI use during and after hospital stay due to hip fracture is associated with a considerable decrease in mortality. These findings could have implications for hip fracture treatment.

Keywords

Epidemiology Hip fracture In-hospital Mortality Osteoporosis Proton pump inhibitors 

Notes

Acknowledgements

We thank Katrin Danninger (OÖGKK), Alexandra Ferdin (BVA), Jana Fischer (NÖGKK), Peter Haubenberger (SVA), Michael Hueber (VAEB), Renato Kasseroller (SGKK), Claudia Kastelic (SVB), Tobias Lingenhöle (VGKK), Ursula Riess (KGKK), Marianne Schmid (StGKK), Cornelia Siess (WGKK), and Norbert Thiemann (TGKK) from the Austrian social insurance authorities for provision of the data.

Compliance with ethical standards

The local ethics committee approved the study which was performed in agreement with the Declaration of Helsinki.

Conflict of interest

None.

Supplementary material

198_2017_3910_MOESM1_ESM.pdf (375 kb)
ESM 1 (PDF 374 kb)

References

  1. 1.
    Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018. doi: 10.1016/S0140-6736(06)68891-0 CrossRefPubMedGoogle Scholar
  2. 2.
    Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi: 10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390. doi: 10.7326/0003-4819-152-6-201003160-00008 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM (2010) Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 16:e228–e234PubMedGoogle Scholar
  5. 5.
    Desilets AR, Asal NJ, Dunican KC (2012) Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm 27:114–120. doi: 10.4140/TCP.n.2012.114 CrossRefPubMedGoogle Scholar
  6. 6.
    Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, Cattabiani C, Lattanzio F, Ruggiero C, Nouvenne A, Meschi T, Bandinelli S, Ferrucci L (2013) Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57:437–442. doi: 10.1016/j.bone.2013.09.014 CrossRefPubMedGoogle Scholar
  7. 7.
    Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259. doi: 10.1007/s00223-008-9170-1 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Amoako AO, Jafilan L, Nasiri P, Pujalte GG (2016) Correlation of bone mineral density scores and proton pump inhibitors use in the elderly. Curr Rheumatol Rev 12:162–166. doi: 10.2174/1573397111666151026222921 CrossRefPubMedGoogle Scholar
  9. 9.
    Kwok CS, Yeong JK-Y, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48:768–776. doi: 10.1016/j.bone.2010.12.015 CrossRefPubMedGoogle Scholar
  10. 10.
    Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106:1209–1218. doi: 10.1038/ajg.2011.113 CrossRefPubMedGoogle Scholar
  11. 11.
    Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J (2011) Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 23:794–800. doi: 10.1097/MEG.0b013e328348a56a CrossRefPubMedGoogle Scholar
  12. 12.
    Yu WE, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526. doi: 10.1016/j.amjmed.2011.01.007 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 27:339–347. doi: 10.1007/s00198-015-3365-x CrossRefPubMedGoogle Scholar
  14. 14.
    Bodmer M, Meier C, Kraenzlin ME, Meier CR (2010) Proton pump inhibitors and fracture risk: true effect or residual confounding? Drug Saf 33:843–852. doi: 10.2165/11536780-000000000-00000 CrossRefPubMedGoogle Scholar
  15. 15.
    Vakil N (2012) Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 72:437–445. doi: 10.2165/11599320-000000000-00000 CrossRefPubMedGoogle Scholar
  16. 16.
    O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781. doi: 10.1016/j.amjmed.2005.02.007 CrossRefPubMedGoogle Scholar
  17. 17.
    Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25CrossRefPubMedGoogle Scholar
  18. 18.
    Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22:903–910. doi: 10.1007/s00198-010-1337-8 CrossRefPubMedGoogle Scholar
  19. 19.
    Yang Y-X, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953. doi: 10.1001/jama.296.24.2947 CrossRefPubMedGoogle Scholar
  20. 20.
    Fisher L, Fisher A, Pavli P, Davis M (2007) Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther 25:297–308. doi: 10.1111/j.1365-2036.2006.03187.x CrossRefPubMedGoogle Scholar
  21. 21.
    Singh R, Trickett R, Meyer LC, Lewthwaite S, Ford D (2016) Prophylactic proton pump inhibitors in femoral neck fracture patients—a life - and cost-saving intervention. Ann R Coll Surg Engl 98:371–375. doi: 10.1308/rcsann.2016.0106 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Franceschi M, Di Mario F, Leandro G, Maggi S, Pilotto A (2009) Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 23:839–848. doi: 10.1016/j.bpg.2009.10.004 CrossRefPubMedGoogle Scholar
  23. 23.
    Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97. doi: 10.1359/jbmr.090704 CrossRefPubMedGoogle Scholar
  24. 24.
    Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Anti-resorptive therapy and risk of mortality and re-fracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396. doi: 10.1007/s00198-015-3415-4 CrossRefPubMedGoogle Scholar
  25. 25.
    Brozek W, Reichardt B, Kimberger O, Zwerina J, Dimai HP, Kritsch D, Klaushofer K, Zwettler E (2014) Mortality after hip fracture in Austria 2008–2011. Calcif Tissue Int 95:257–266. doi: 10.1007/s00223-014-9889-9 CrossRefPubMedGoogle Scholar
  26. 26.
    Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252. doi: 10.1007/s00198-012-2024-8 CrossRefPubMedGoogle Scholar
  27. 27.
    Abrahamsen B, Eiken P, Eastell R (2011) Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 171:998–1004. doi: 10.1001/archinternmed.2011.20 PubMedGoogle Scholar
  28. 28.
    Lee J, Youn KE, Choi N-K, Lee J-H, Kang DY, Song H-J, Park B-J (2013) A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 48:1016–1022. doi: 10.1007/s00535-012-0722-9 CrossRefPubMedGoogle Scholar
  29. 29.
    Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F (2006) Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur J Clin Pharmacol 62:65–73. doi: 10.1007/s00228-005-0027-5 CrossRefPubMedGoogle Scholar
  30. 30.
    Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589. doi: 10.1007/s00198-004-1780-5 CrossRefPubMedGoogle Scholar
  31. 31.
    Reyes C, Estrada P, Nogués X, Orozco P, Cooper C, Díez-Pérez A, Formiga F, González-Macías J, Prieto-Alhambra D (2014) The impact of common co-morbidities (as measured by the Charlson index) on hip fracture risk in elderly men: a population-based cohort study. Osteoporos Int 25:1751–1758. doi: 10.1007/s00198-014-2682-9 CrossRefPubMedGoogle Scholar
  32. 32.
    Moore RA, Derry S, Simon LS, Emery P (2014) Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract 14:378–395. doi: 10.1111/papr.12100 CrossRefPubMedGoogle Scholar
  33. 33.
    Santalucia P, Franchi C, Djade CD, Tettamanti M, Pasina L, Corrao S, Salerno F, Marengoni A, Marcucci M, Nobili A, Mannucci PM (2015) Gender difference in drug use in hospitalized elderly patients. Eur J Intern Med 26:483–490. doi: 10.1016/j.ejim.2015.07.006 CrossRefPubMedGoogle Scholar
  34. 34.
    Chow LWC, Gertsch P, Poon RTP, Branicki FJ (1998) Risk factors for rebleeding and death from peptic ulcer in the very elderly. Br J Surg 85:121–124. doi: 10.1046/j.1365-2168.1998.00665.x CrossRefPubMedGoogle Scholar
  35. 35.
    Bini EJ, Cohen J (2003) Endoscopic treatment compared with medical therapy for the prevention of recurrent ulcer hemorrhage in patients with adherent clots. Gastrointest Endosc 58:707–714. doi: 10.1016/S0016-5107(03)02014-5 CrossRefPubMedGoogle Scholar
  36. 36.
    Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC (2011) Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 84:102–113. doi: 10.1159/000323958 CrossRefPubMedGoogle Scholar
  37. 37.
    Masclee GMC, Sturkenboom MCJM, Kuipers EJ (2014) A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging 31:263–282. doi: 10.1007/s40266-014-0166-4 CrossRefPubMedGoogle Scholar
  38. 38.
    Corleto VD, Festa S, Di Giulio E, Annibale B (2014) Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 21:3–8. doi: 10.1097/MED.0000000000000031 CrossRefPubMedGoogle Scholar
  39. 39.
    Wilhelm SM, Rjater RG, Kale-Pradhan PB (2013) Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 6:443–451. doi: 10.1586/17512433.2013.811206 CrossRefPubMedGoogle Scholar
  40. 40.
    Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301:2120–2128. doi: 10.1001/jama.2009.722 CrossRefPubMedGoogle Scholar
  41. 41.
    Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790. doi: 10.1001/archinternmed.2010.89 CrossRefPubMedGoogle Scholar
  42. 42.
    Pappas M, Jolly S, Vijan S (2016) Defining appropriate use of proton-pump inhibitors among medical inpatients. J Gen Intern Med 31:364–371. doi: 10.1007/s11606-015-3536-7 CrossRefPubMedGoogle Scholar
  43. 43.
    Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E (2016) The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. doi: 10.1016/j.ejim.2016.10.007 PubMedGoogle Scholar
  44. 44.
    Thaler HW, Dovjak P, Iglseder B, Pinter G, Müller E, Müller W, Pils K, Mikosch P, Gerstorfer I, Zmaritz M, Weissenberger-Leduc M, Gosch M (2013) Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures. Wien Med Wochenschr 163:442–447. doi: 10.1007/s10354-013-0234-0 CrossRefPubMedGoogle Scholar
  45. 45.
    Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, Jick H, Johnson CC (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968. doi: 10.1002/pds.1454 CrossRefPubMedGoogle Scholar
  46. 46.
    Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435–2442. doi: 10.1001/jama.2013.280490 CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Authors and Affiliations

  1. 1.Ludwig Boltzmann Institute of OsteologyHanusch Hospital of the WGKK and AUVA Trauma Center, 1st Medical Department at Hanusch HospitalViennaAustria
  2. 2.Sickness Fund Burgenland, Burgenländische GebietskrankenkasseEisenstadtAustria
  3. 3.Department of Internal Medicine, Division of Endocrinology and DiabetologyMedical University of GrazGrazAustria

Personalised recommendations